Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About BetterLife Pharma Inc.
BetterLife Pharma, Inc. is a biotechnology company, which engages in the business of developing compounds for the treatment of mental disorders. The company is headquartered in Vancouver, British Columbia and currently employs 4 full-time employees. The company went IPO on 2017-12-19. The firm is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations and cardiac toxicity. BETR-001 is a therapy to treat debilitating psychiatric disorders with high unmet need, such as major depressive disorder and anxiety disorders; as well as neurological disorders such as neuropathic pain. BETR-002 is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound for treatment of benzodiazepine dependency, anxiety and spasticity. The firm also owns a drug candidate for the treatment of viral infections such as COVID-19. The Company’s subsidiaries include MedMelior Inc., BetterLife Pharma US Inc. and Blife Therapeutics Inc.
Industry: Pharmaceutical Preparations Peers: Lexaria Bioscience Corp.
